特拉唑嗪与氯美扎酮联合治疗慢性前列腺炎/慢性盆腔疼痛综合征的回顾性分析

[Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome].

作者信息

Yan Su, Li Han-Zhong, Zhang Xin-Yu, Li Hong-Jun

机构信息

Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.

出版信息

Zhonghua Nan Ke Xue. 2009 Aug;15(8):717-20.

PMID:19852273

Abstract

OBJECTIVE

To investigate the efficacy and safety of the alpha1-receptor inhibitor terazosin combined with chlormezanone in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

METHODS

A total of 168 CPPS patients, aged 20 -50 (mean 32.9) years and with the disease course of 3 months to 7 years (mean 17 months), were equally randomized into a terazosin group (n = 58), a chlormezanone group (n = 38) and a terazosin + chlormezanone (T + C) group (n = 72), and treated accordingly for 4 weeks. All the patients were scored on NIH-CPSI (National Institute of Health-Chronic Prostatitis Symptom Index) after the treatment and the therapeutic effects were compared among the three groups.

RESULTS

Of the total number of patients, 159 completed the treatment and were evaluated, including 55 of the terazosin group, 35 of the chlormezanone group and 69 of the T + C group. After the treatment, the NIH-CPSI scores of the three groups decreased from 24.05 +/- 3.02 to 16.15 +/- 3.25 (mean 7.90), from 23.43 +/- 3.58 to 17.51 +/- 3.08 (mean 5.92), and from 23.93 +/- 3.30 to 15.01 +/- 3.08 (mean 8.92), respectively, with statistically significant differences from pretreatment (P < 0.05) as well as between the combined therapy group and the other two (P < 0.05). The adverse events included postural hypotension (17.1% in the terazosin group and 15.4% in the T + C group), dysspermatism (3.4% in the terazosin group only), lassitude, fatigue and anorexia (18.5% in the chlormezanone group and 12.6% in the T + C group). Nine of the patients failed to accomplish the treatment because of adverse events, 3 (5.2%) in the terazosin group, 3 (7.9%) in the chlormezanone group and 3 (12.6%) in the T + C group.

CONCLUSION

Both terazosin and chlormezanone can relieve the symptoms in CP/CPPS patients and improve their life quality, but their combined use may produce a better efficacy than either terazosin or chlormezanone used alone.

摘要

目的

探讨α1受体抑制剂特拉唑嗪联合氯美扎酮治疗慢性前列腺炎/慢性盆腔疼痛综合征（CP/CPPS）的疗效及安全性。

方法

将168例年龄在20 - 50岁（平均32.9岁）、病程3个月至7年（平均17个月）的CPPS患者，随机分为特拉唑嗪组（n = 58）、氯美扎酮组（n = 38）和特拉唑嗪 + 氯美扎酮（T + C）组（n = 72），分别进行4周治疗。治疗后所有患者采用美国国立卫生研究院慢性前列腺炎症状指数（NIH-CPSI）评分，比较三组疗效。

结果

159例患者完成治疗并进行评估，其中特拉唑嗪组55例，氯美扎酮组35例，T + C组69例。治疗后，三组NIH-CPSI评分分别从24.05±3.02降至16.15±3.25（平均下降7.90）、从23.43±3.58降至17.51±3.08（平均下降5.92）、从23.93±3.30降至15.01±3.08（平均下降8.92），与治疗前比较差异有统计学意义（P < 0.05），联合治疗组与其他两组比较差异有统计学意义（P < 0.05）。不良事件包括体位性低血压（特拉唑嗪组17.1%，T + C组15.4%）、射精障碍（仅特拉唑嗪组3.4%）、倦怠、乏力和食欲减退（氯美扎酮组18.5%，T + C组12.6%）。9例患者因不良事件未完成治疗，特拉唑嗪组3例（5.2%），氯美扎酮组3例（7.9%），T + C组3例（12.6%）。